SMMT ▲ +3.6% - Summit Therapeutics Inc. $SMMT Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China Summit Therapeutics' stock rose 3.6% following positive Phase 3 trial results for ivonescimab monotherapy, which showed statistically significant and clinically meaningful superiority over pembrolizumab monotherapy in treating PD-L1-positive advanced non-small cell lung cancer in the HARMONi-2 study. The favorable efficacy data from this China-based trial supports the drug candidate's potential in a major cancer indication and bolsters the company's development pipeline. 13-SEP-2026 08:10 AM ET